MARKET

BMY

BMY

Bristol-Myers Squibb Co
NYSE
53.36
-0.20
-0.36%
Opening 15:10 12/18 EST
OPEN
53.32
PREV CLOSE
53.55
HIGH
53.80
LOW
53.09
VOLUME
9.65M
TURNOVER
--
52 WEEK HIGH
61.00
52 WEEK LOW
42.38
MARKET CAP
108.62B
P/E (TTM)
18.01
1D
5D
1M
3M
1Y
5Y
1D
BMY and BNTX Advance New Immunotherapy Bet in First-Line Liver Cancer With ROSETTA HCC-206
TipRanks · 6h ago
White House Readies Drug Price Deals With AbbVie, Novartis, Roche
Benzinga · 7h ago
Press Release: Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026
Dow Jones · 10h ago
Cytokinetics upgraded to Buy at Goldman on odds of ACACIA succeeding
TipRanks · 11h ago
SCHD: This ETF Stinks
Seeking Alpha · 23h ago
These 2 Healthcare Stocks Just Declared Dividend Raises
The Motley Fool · 1d ago
More pharmas expected to sign drug pricing deals with Trump on Friday - report
Seeking Alpha · 1d ago
Bristol-Myers Squibb to Launch Phase 3 Trial for Schizophrenia Drug KarXT in Adolescents
TipRanks · 1d ago
More
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.

Webull offers Bristol-Myers Squibb Co stock information, including NYSE: BMY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BMY stock methods without spending real money on the virtual paper trading platform.